Data from Clinical Trial of Satraplatin for the Treatment of Hormone- Refractory Prostate Cancer Published in 'Oncology'

GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; Nasdaq: GPCB) today announced the publication in the peer-reviewed journal, Oncology, of a 50-patient randomized clinical trial evaluating the Company's lead drug candidate, satraplatin, as first-line chemotherapy for the treatment of patients with hormone-refractory prostate ca...

Continue to Data from Clinical Trial of Satraplatin for the Treatment of Hormone- Refractory Prostate Cancer Published in 'Oncology' on Medical News Today.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz